Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 4/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | BCL6 | P41182 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31728177 | 0.83 | NUDT1 (0.46) | NUDT1CDK4CCNE1CDK2HRH4 | |
| SCHEMBL2032467 | 0.81 | NUDT1 (0.49) | NUDT1HSD17B10CDK4CCNE1CDK2 | |
| SCHEMBL25722559 | 0.79 | NUDT1 (0.46) | NUDT1CDK4CCNE1CDK2HRH4 | |
| SCHEMBL18879260 | 0.79 | NUDT1 (0.47) | NUDT1CDK4CCNE1CDK2HRH4 | |
| SCHEMBL3646434 | 0.79 | NUDT1 (0.47) | NUDT1CDK4CCNE1CDK2HRH4 | |
| SCHEMBL19406906 | 0.79 | NUDT1 (0.38) | NUDT1HSD17B10CDK4CCNE1CDK2 | |
| SCHEMBL30230348 | 0.77 | HSP90AA1 (0.45) | NUDT1HSD17B10CDK2HRH4HSP90AA1 | |
| SCHEMBL345262 | 0.77 | HSP90AA1 (0.45) | NUDT1HSD17B10CDK2HRH4HSP90AA1 | |
| SCHEMBL27946089 | 0.77 | NUDT1 (0.41) | NUDT1CDK4CCNE1CDK2HRH4 | |
| Hydrochloric Acid SCHEMBL31336789 | 0.76 | LOXL2 (0.44) | NUDT1HSD17B10CDK2HRH4HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2024-06-27 | — | — | US | disclosed |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2024-06-27 | — | — | US | disclosed |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11713290-B2 | Cycloheptylamine derivatives as anti-diabetic agents | UNITED ARAB EMIRATES UNIVERSITY (AE) | 2023-08-01 | — | — | US | disclosed |
| US-11713290-B2 | Cycloheptylamine derivatives as anti-diabetic agents | UNITED ARAB EMIRATES UNIVERSITY (AE) | 2023-08-01 | — | — | US | disclosed |
| US-20230212143-A9 | PRMT5 INHIBITOR COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212143-A9 | PRMT5 INHIBITOR COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2023-02-02 | — | — | US | disclosed |
| US-11433065-B2 | Certain chemical entities, compositions and methods | INTELLIKINE LLC (US) | 2022-09-06 | — | — | US | disclosed |
| US-20090005359-A1 | Heterocyclic Compounds Useful as RAF Kinase Inhibitors | SUNESIS PHARMACEUTICALS, INC (US) | 2009-01-01 | — | — | US | disclosed |
| US-20090005359-A1 | Heterocyclic Compounds Useful as RAF Kinase Inhibitors | SUNESIS PHARMACEUTICALS, INC (US) | 2009-01-01 | — | — | US | disclosed |
| US-7429604-B2 | Six-membered heterocycles useful as serine protease inhibitors | BRISTOL MYERS SQUIBB COMPANY (US) | 2008-09-30 | — | — | US | disclosed |
| US-20080139505-A1 | Potentiators Of Glutamate Receptors | ARRAY BIOPHARMA, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080139505-A1 | Potentiators Of Glutamate Receptors | ARRAY BIOPHARMA, INC. | 2008-06-12 | — | — | US | disclosed |
| US-20080096930-A1 | 1-(2-hydroxy-3-methyl-4-{4-[4-(1H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-phenyl)-ethanone; 6-(3-((4-acetyl-3-hydroxy-2-propylphenoxy)methyl)phenylthio)isonicotinic acid; 1-(2-hydroxy-4-{3-[4-(2H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-3-trifluoromethyl-phenyl)-ethanone; treatment of migriane | ARRAY BIOPHARMA, INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080096930-A1 | 1-(2-hydroxy-3-methyl-4-{4-[4-(1H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-phenyl)-ethanone; 6-(3-((4-acetyl-3-hydroxy-2-propylphenoxy)methyl)phenylthio)isonicotinic acid; 1-(2-hydroxy-4-{3-[4-(2H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-3-trifluoromethyl-phenyl)-ethanone; treatment of migriane | ARRAY BIOPHARMA, INC. | 2008-04-24 | — | — | US | disclosed |
| US-20080004321-A1 | 3-{[4-(4-acetyl-3-hydroxy-2-propylphenoxymethyl)-phenyl]-(S)-hydroxymethyl}-benzoic acid; anxiolytic, neuroleptic agent and antidepressant as glutamate receptor agonist; antiinflammatory agent as leukotriene receptor agonist; | ELI LILLY AND COMPANY | 2008-01-03 | — | — | US | disclosed |
| US-20080004321-A1 | 3-{[4-(4-acetyl-3-hydroxy-2-propylphenoxymethyl)-phenyl]-(S)-hydroxymethyl}-benzoic acid; anxiolytic, neuroleptic agent and antidepressant as glutamate receptor agonist; antiinflammatory agent as leukotriene receptor agonist; | ELI LILLY AND COMPANY | 2008-01-03 | — | — | US | disclosed |
| WO-2006057870-A1 | POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139505-A1 | Potentiators Of Glutamate Receptors | GRM1, GRIN1, GRM2 | NUDT1 2487/4885HSD17B10 2113/4885CDK4 3564/4885 |
| US-11713290-B2 | Cycloheptylamine derivatives as anti-diabetic agents | BHMT2, BHMT, GPR119 | NUDT1 190/4885HSD17B10 3335/4885CDK4 1640/4885 |
| US-20240209000-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CD | NUDT1 1041/4885HSD17B10 1877/4885CDK4 166/4885 |
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | ROCK1, ROCK2, RHOA | NUDT1 3259/4885HSD17B10 2976/4885CDK4 2323/4885 |
| US-20090005359-A1 | Heterocyclic Compounds Useful as RAF Kinase Inhibitors | BRAF, RAF1, ARAF | NUDT1 1492/4885HSD17B10 2872/4885CDK4 68/4885 |
| US-20230364097-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | NUDT1 1478/4885HSD17B10 2119/4885CDK4 50/4885 |
| US-20080096930-A1 | 1-(2-hydroxy-3-methyl-4-{4-[4-(1H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-phenyl)-ethanone; 6-(3-((4-acetyl-3-hydroxy-2-propylphenoxy)methyl)phenylthio)isonicotinic acid; 1-(2-hydroxy-4-{3-[4-(2H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-3-trifluoromethyl-phenyl)-ethanone; treatment of migriane | HTR7, UGT2B7, HK1 | NUDT1 362/4885HSD17B10 1073/4885CDK4 281/4885 |
| US-20230212143-A9 | PRMT5 INHIBITOR COMPOUNDS | PRMT5, PRMT1, PRMT6 | NUDT1 3251/4885HSD17B10 2879/4885CDK4 1434/4885 |
| US-20080004321-A1 | 3-{[4-(4-acetyl-3-hydroxy-2-propylphenoxymethyl)-phenyl]-(S)-hydroxymethyl}-benzoic acid; anxiolytic, neuroleptic agent and antidepressant as glutamate receptor agonist; antiinflammatory agent as leukotriene receptor agonist; | LTB4R, LTB4R2, CYSLTR1 | NUDT1 2286/4885HSD17B10 884/4885CDK4 1997/4885 |
| US-11433065-B2 | Certain chemical entities, compositions and methods | PIK3CA, AKT3, PIK3C2A | NUDT1 1283/4885HSD17B10 3125/4885CDK4 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.